Individuals with T2DM frequently have multiple cardiovascular risk factors, including obesity (32.9%), hypertension (32-80%), and dyslipidemia (39%) ( The association between glycemic control and cardiovascular outcomes in DM patients has been long studied ( To address these challenges, novel pharmacological therapies such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged, offering cardioprotective benefits ( The aim of this review is to enhance our understanding of the role of SGLT-2i and GLP-1 RAs in managing patients with T2DM and CVD
It was concluded that alcohol might exacerbate age-related infertility [312]
If youre an emotional eater who has depended on food to reduce your stress, numb your feelings, cope with depression, what will you do without the comfort and distraction of food once Ozempic has reduced your capacity to eat
Zepbound (Tirzepatide): Regarded as a new generation weight loss medication, tirzepatide targets both GLP-1 and GIP receptors, offering enhanced appetite suppression and metabolic improvements
Most patients report noticing reduced appetite within the first 1-2 weeks at the starting dose (0.25mg for Wegovy)
Possible explanations include rapid changes in body composition, biomechanical adjustment, or dehydration
